. 2024 Mar 1;9(1):1–7. doi: 10.14744/bej.2024.47123

Table 1.

Study characteristics

No	Reference	Study design	Level of evidence	Intervention	Sample size (eye)	Outcome observed
1	2015, Maria Cecilia D Aquino	Randomised Controlled Trial	2	MP-CPC vs. CW-CPC	48	success rate; IOP at baseline, 1^st day, 1^st week, 1^st, 3^rd, 6^th, 12^th, 18^th month; antiglaucoma medications; complications
2	2018, Ahmed M. Abdelrahman	Prospective Cohort	2	MP-CPC vs. CW-CPC	45	success rate; IOP at baseline, 2^nd week, 1^st, 3^rd, 6^th month; antiglaucoma medications; complications
3	2020, Anthony Fam	Retrospective Cohort	2	MP-CPC vs. CW-CPC	31	IOP at baseline, 1^st, 3^rd, 6^th, 12^th month, antiglaucoma medications, retreatments
3	2020, A. M. Abdullatif	Randomised Controlled Trial	2	HFU vs. MP-CPC vs. CW-CPC	30	success rate; IOP at baseline, 1^st day, 1^st, 2^nd week, 1^st, 2^nd, 3^rd, 6^th month; antiglaucoma medications; complications
4	2021, Enrico Bernardi	Retrospective Cohort	2	MP-CPC vs. CW-CPC	197	success rate; IOP at baseline, 1^st day, 1^st week, 1^st, 3^rd, 6^th, 9^th, 12^th month, antiglaucoma medications; BCVA
5	2021, Mihail Zemba	Retrospective Cohort	2	MP-CPC vs. CW-CPC	46	success rate; IOP at baseline, 1^st day, 1^st week, 1^st, 3^rd, 6^th, 9^th, 12^th, 15^th month; antiglaucoma medications, complications, BCVA, need for retreatment

MP-CPC: Micro-pulse cyclophotocoagulation; CW-CPC: continuous wave cyclophotocoagulation.